Syntropharma Ltd.
This article was originally published in Start Up
Executive Summary
Syntropharma Ltd. aims to take known drugs that can be improved via transdermal delivery, or gain product life-extension through reformulation in the novel delivery mechanism. The company is focusing on two candidates: a transdermal selegiline patch for depression (aimed at the European market) and a patch formulation of naltrexone, an opioid receptor antagonist for battling dependence on alcohol and opiates.